Sustained Molecular Remission after Arsenic Trioxide and Gemutuzumab Ozogamicin in a Pediatric Patient with Relapsed Acute Promyelocytic Leukemia

Akiko InoueDepartment of Pediatrics, Osaka Medical College, Takatsuki, JapanCorrespondence[email protected]

Chihiro KawakamiDepartment of Pediatrics, Osaka Medical College, Takatsuki, Japan

Kimitaka TakitaniDepartment of Pediatrics, Osaka Medical College, Takatsuki, Japan

Hiroshi TamaiDepartment of Pediatrics, Osaka Medical College, Takatsuki, Japan

REFERENCES

Yoo ES. Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. Korean J Pediatr. 2011;54:95–105.
PubMedGoogle Scholar
Breccia M, Lo-Coco F. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther. 2011;11:225–234.
PubMed Web of Science ®Google Scholar
Ravandi F, Estey E, Jones D, Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504–510.
PubMed Web of Science ®Google Scholar
Mathews V, George B, Chendamarai E, Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866–3871.
PubMed Web of Science ®Google Scholar
Zhou J, Zhang Y, Li J, Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115:1697–1702.
PubMed Web of Science ®Google Scholar
Thirugnanam R, George B, Chendamarai E, Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009;15:1479–1484.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Sustained Molecular Remission after Arsenic Trioxide and Gemutuzumab Ozogamicin in a Pediatric Patient with Relapsed Acute Promyelocytic Leukemia

REFERENCES

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Sustained Molecular Remission after Arsenic Trioxide and Gemutuzumab Ozogamicin in a Pediatric Patient with Relapsed Acute Promyelocytic Leukemia

REFERENCES

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date